Cover Image
市場調查報告書

麻疹:開發中產品分析

Measles - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 251554
出版日期 內容資訊 英文 53 Pages
訂單完成後即時交付
價格
Back to Top
麻疹:開發中產品分析 Measles - Pipeline Review, H2 2016
出版日期: 2016年10月26日 內容資訊: 英文 53 Pages
簡介

麻疹是病毒造成的高傳染性疾病。病毒生長在患者的鼻子黏液和喉嚨。會藉由身體接觸及咳嗽、打噴涕擴大傳染。麻疹最常見的症狀有高燒、眼疾(結膜炎)、最初流鼻涕、第1日以後在口內出現大量白色斑點。這樣的症狀持續數天,伴隨嚴重的乾咳。也常有腹瀉和嘔吐,一般兒童持續3∼5天後整體身體狀況就會嚴重衰弱並沈睡。

本報告提供靜脈性腳潰瘍 (小腿潰瘍) 的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃相關資訊等,以及最新的新聞和發表。

簡介

  • 調查範圍

麻疹概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

麻疹:企業開發中的治療藥

麻疹:大學/機關研究中的治療藥

麻疹:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

麻疹:企業開發中的產品

麻疹:大學/機關研究中的產品

麻疹的治療藥開發企業

  • Beijing Minhai Biotechnology Co., Ltd
  • Beijing Tiantan Biological Products Co., Ltd.
  • Biological E. Limited
  • China National Pharmaceutical Group Corporation
  • 第一三共
  • GlaxoSmithKline Plc
  • Prometheon Pharma, LLC
  • Sinovac Biotech Ltd.
  • Vical Incorporated
  • Zydus Cadila Healthcare Limited

麻疹:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

麻疹:最近的開發平台趨勢

麻疹:暫停中的計劃

麻疹:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8572IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Measles - Pipeline Review, H2 2016, provides an overview of the Measles (Infectious Disease) pipeline landscape.

Measles is a highly infectious viral disease. The virus lives in the mucus of the nose and throat of people with this infection. Physical contact, coughing and sneezing can spread the infection. Symptoms of measles are high temperature, sore eyes (conjunctivitis), and a runny nose usually occur first, small white spots usually develop inside the mouth a day or so later, diarrhea and vomiting.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Measles - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Measles (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Measles (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Measles and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 1, 2, 1, 4 and 1 respectively for Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively for Measles.

Measles (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Measles (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Measles (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Measles (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Measles (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Measles (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Measles (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Measles (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Measles Overview
  • Therapeutics Development
    • Pipeline Products for Measles - Overview
    • Pipeline Products for Measles - Comparative Analysis
  • Measles - Therapeutics under Development by Companies
  • Measles - Therapeutics under Investigation by Universities/Institutes
  • Measles - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Measles - Products under Development by Companies
  • Measles - Products under Investigation by Universities/Institutes
  • Measles - Companies Involved in Therapeutics Development
    • Beijing Minhai Biotechnology Co., Ltd
    • Beijing Tiantan Biological Products Co., Ltd.
    • Biological E. Limited
    • Daiichi Sankyo Company, Limited
    • GlaxoSmithKline Plc
    • Prometheon Pharma, LLC
    • Sinovac Biotech Ltd.
    • VBI Vaccines Inc
    • Vical Incorporated
    • Zydus Cadila Healthcare Limited
  • Measles - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (measles + mumps + rubella + varicella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles + mumps + rubella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles + mumps + rubella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles + mumps + rubella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles + rubella + varicella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles + rubella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles + rubella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles [strain Schwarz] + mumps [strain RIT 4385] + rubella [strain Wistar RA 27/3]) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ERDRP-0519 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • measles (bivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • measles + mumps + rubella + varicella vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • measles vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • measles vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VN-0102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Measles - Dormant Projects
  • Measles - Product Development Milestones
    • Featured News & Press Releases
      • Aug 21, 2008: Vaxfectin Formulated Measles DNA Vaccine Could Address Unmet Need for Infants
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Measles, H2 2016
  • Number of Products under Development for Measles - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Measles - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2016
  • Measles - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H2 2016
  • Measles - Pipeline by Biological E. Limited, H2 2016
  • Measles - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
  • Measles - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Measles - Pipeline by Prometheon Pharma, LLC, H2 2016
  • Measles - Pipeline by Sinovac Biotech Ltd., H2 2016
  • Measles - Pipeline by VBI Vaccines Inc, H2 2016
  • Measles - Pipeline by Vical Incorporated, H2 2016
  • Measles - Pipeline by Zydus Cadila Healthcare Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Measles - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Measles, H2 2016
  • Number of Products under Development for Measles - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top